A Study of An Adjuvanted Inactivated H7N9 Influenza Vaccine - Trial NCT03755427
Access comprehensive clinical trial information for NCT03755427 through Pure Global AI's free database. This Phase 2 trial is sponsored by Shanghai Institute Of Biological Products and is currently status unknown. The study focuses on H7N9 Influenza. Target enrollment is 560 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Shanghai Institute Of Biological Products
Timeline & Enrollment
Phase 2
Nov 01, 2018
Jan 01, 2020
Primary Outcome
Number of Subjects Reporting Solicited and Unsolicited Adverse Events (AEs)
Summary
The aim of this study is to investigate the immunogenicity and safety of the inactivated
 whole-virion vaccine for teenagers and adults.
 
 The investigators will test the vaccine in participants aged above 12 years, for a
 randomized, blind, placebo-controlled, clinical study. The investigators designed one dosage
 groups: 15 ฮผg of hemagglutinin antigen. Control group is designed to inoculate seasonal
 influence vaccine and aluminum hydroxide adjuvant. Participants will receive 2 doses of
 vaccine at 21-day intervals. Safety up to 6 months and changes in hemagglutinin inhibition
 (HI) titers at 21 days after each vaccination will be determined.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT03755427
Non-Device Trial